Home   |   About Journal   |   Editorial Board   |   Instruction   |   Subscriptions   |   Contacts Us   |   中文
journal1  2022, Vol. 42 Issue (6): 17-19    DOI: 10.3969/j.issn.1001-8131.2022.06.007
Current Issue | Archive | Adv Search |
Clinical Efficacy of Somatostatin Analogues Combined With Everolimus in the Treatment of Pancreatic Neuroendocrine Tumors
Chen Xiaolan, Shang Qingling, Li Hui
Xinyang First People's Hospital,Department of Endocrinology, Xinyang 464000, China
Download: PDF (427 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  Objective To observe the clinical efficacy of somatostatin analogists combined with everolimus in the treatment of pancreatic neuroendocrine tumors. Methods A total of 54 patients with pancreatic neuroendocrine tumor admitted to our hospital were selected and divided into observation group(n=27)and control group(n=27)according to random number table method.The control group was treated with somatostatin analogue,and the observation group was treated with somatostatin analogue combined with everolimus.The treatment effect,time to progression,recurrence rate 1-3 years after operation,serum CgA level and the incidence of related complications were compared between the two groups. Results The time to progression in the observation group was significantly longer than that in the control group,and the 1-3 years recurrence rate was significantly lower than that in the control group(P<0.05).After 3 months of treatment,the serum CGA level in the observation group was significantly lower than that in the control group(P<0.05).However,the incidence of adverse reactions(mainly oral inflammation)in the observation group was significantly higher than that in the control group(P<0.05). Conclusion The clinical efficacy of somatostatin analogue combined with everolimus in the treatment of pancreatic neuroendocrine tumors is better than that of somatostatin analogue alone,which can prolong the time to progression and reduce disease recurrence in patients.However,the incidence of adverse reactions in patients taking everolimus is higher,which needs to be solved clinically.
Key wordsSomatostatin analogue      Everolimus      Pancreatic neuroendocrine tumor     
Received: 25 August 2021     
PACS:  R735.9  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Chen Xiaolan
Shang Qingling
Li Hui
Cite this article:   
Chen Xiaolan,Shang Qingling,Li Hui. Clinical Efficacy of Somatostatin Analogues Combined With Everolimus in the Treatment of Pancreatic Neuroendocrine Tumors[J]. journal1, 2022, 42(6): 17-19.
URL:  
http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2022.06.007     OR     http://www.hrbyybjb.org.cn/EN/Y2022/V42/I6/17
Copyright © Editorial Board of journal1
Supported by:Beijing Magtech